NCT06668896尚未招募1 期
An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone Intravaginal Ring (IVR) 8 mg and 12 mg/Day Versus Progesterone Vaginal Insert 100mg
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 60
- 主要终点
- Systemic pharmacokinetics of progesterone, Concentration over 24 hours
研究概览
简要总结
This study is looking for healthy female adults to use an vaginal ring with differing amounts of the hormone progesterone and go through a series of blood draws to measure how much progesterone is in the body following the use of these vaginal rings over an extended period of time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Individuals assigned female at birth who are post-menopausal, women 40 to 65 years of age, inclusive. Postmenopausal is defined as 6-months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL (if not taking systemic hormone therapy) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •Able and willing to correctly and independently complete all study procedures.
- •Able to read, understand, and provide written informed consent after the nature of the study has been fully explained and must be willing to comply with all study requirements and procedures.
- •VA vaginal pH of ≤ 5.
- •Women with vaginal atrophy may rescreen at least 6 weeks after starting either systemic or topical estradiol therapy.
- •Women who are taking systemic (e.g. oral, injectable, transdermal) progesterone (P4) therapy must have at least 2 weeks of wash out from the last dose prior to visit 2.
排除标准
- •Subjects with clinically significant chronic kidney disease defined as Glomerular Filtration Rate of <60 mL/min/1.73m2
- •Subjects with uninvestigated hematuria
- •Subjects with known nephrolithiasis, known polycystic kidney disease (PKD), or other known renal genetic disorders
- •Subjects with prior pelvic malignancies requiring radiation therapy, or whose surgery for such has led to complications such as fistulas, etc.
- •Subjects with a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into the trial. This includes but is not limited to the following:
- •Active chronic hepatitis B or hepatitis C infection including hepatitis B surface antigen and hepatitis C antigen positive patients with or without abnormal liver enzymes
- •Concurrent neurodegenerative disease
- •Cardiovascular: uncontrolled hypertension, unstable angina, myocardial infarction or symptomatic congestive heart failure within the past 6 months or serious uncontrolled cardiac arrhythmia or use of Class 1 antiarrhythmic
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of the protocol
- •Subjects with hypersensitivity toward any ingredients in the study treatments.
- •Participation in any other investigational drug or device trial in which administration of an investigational study drug/device occurred within 30 days or placement of a non-drug eluting medical device within 15 days prior to the Screening Visit (Visit 1). This does not include re-enrollments into this study, who require at least 14 days of washout prior to re-enrollment.
研究组 & 干预措施
DARE-PTB1 8mg IVR
Experimental
Intravaginal ring containing 8mg progesterone administered once for 14 days.
干预措施: Progesterone (Drug)
DARE-PTB1 12mg IVR
Experimental
Intravaginal ring containing 12mg progesterone administered once for 14 days.
干预措施: Progesterone (Drug)
DARE-PTB1 12mg IVR every 3 days
Experimental
Intravaginal ring containing 12mg progesterone administered every 3 days for 15 days.
干预措施: Progesterone (Drug)
Endometrin 100mg
Active Comparator
100mg progesterone vaginal insert, three times daily for 14 days.
干预措施: Progesterone (Drug)
结局指标
主要结局
Systemic pharmacokinetics of progesterone, Concentration over 24 hours
时间窗: 14 days
Describe the concentration of progesterone (P4) in blood prior to, during and after 24 hours of DARE-PTB1 IVR (8mg and 12mg) over 14 days of use.
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)Contraception: Optional Applicator for Insertion of Vaginal RingNCT02275546Organon and Co164
已完成
1 期
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIngHuman Immunodeficiency VirusNCT01755741International Partnership for Microbicides, Inc.70
已完成
早期 1 期
A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery MethodHIV InfectionsNCT00469170International Partnership for Microbicides, Inc.220
已完成
2 期
A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)DysmenorrheaNCT01670656Organon and Co439
已完成
2 期
Assessment of a Vaginal Ring With Meloxicam in the Treatment of DysmenorrheaDysmenorrheaNCT02255045Laboratorios Andromaco S.A.68